Alcami, a United States-based contract-development and manufacturing organisation (CDMO), announced on Tuesday that it is partnering with Civica Inc. (Civica Rx), a US-based non-profit pharmaceutical company that said it is focused on ensuring quality generic medicines.
According to the contract, Alcami is to provide analytical support for products to be manufactured at Civica's 140,000 square-foot sterile injectable manufacturing facility in Petersburg, Virginia. Alcami's network of laboratories across the United States are to support Civica's program with method establishment, validation, release, and stability for excipients, drug substances, and drug products, along with formulation development support. Timothy Compton, Alcami chief business officer, said, 'We are proud to support Civica and the important work they are doing to ensure the supply of high-quality generic medicines in the United States. The support we have been engaged to provide is a testament to our broad capabilities, technical expertise, and ability to collaborate with customers to deliver high-quality results consistently.'
Breckenridge Pharmaceutical signs new-product agreement with PTS Pharma
Dr. Reddy's Laboratories Launches Posaconazole Delayed-Release Tablets in the US Market
Nexus Pharmaceuticals unveils Erythromycin Lactobionate for Injection, USP in 500mg/vial
Breckenridge Pharmaceutical, Inc launches Pencillamine Capsules, USP
Breckenridge Pharmaceutical launches Lacosamide Tablets
Milla announces third ANDA approval & fourth US approval for the Alter Pharma Group